Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window About a year was ...

Please provide your email address to receive an email when new articles are posted on . A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or ...

1. American College of Physicians recommends bisphosphonates for initial treatment for osteoporosis in males and postmenopausal females diagnosed with primary ...

Please provide your email address to receive an email when new articles are posted on . The reduced risks for osteoporotic and hip fractures with bisphosphonate therapy outweigh increased risk for ...

Researchers found a small but greater risk of a hip fracture after 2 years of taking a "drug holiday" — stopping therapy — after long-term (≥ 3-year) use of one bisphosphonate, risedronate, versus ...

May 13, 2011— -- Many doctors are changing the prescribing length of a class of osteoporosis medication known as bisphosphonates after mounting evidence has linked long-term use of the medication ...

A real-world cohort study showed no difference in efficacy between denosumab and bisphosphonates in treating inpatients with hypercalcemia of malignancy. “Prospective randomized trials are warranted ...

SEATTLE -- Risk of death was lower in the years after a bisphosphonate was started following a fracture rather than denosumab (Prolia), a target trial emulation found. In adults ages 50 and older who ...

The use of bisphosphonates seems to be associated with the development of ONJ. Length of exposure seems to be the most important risk factor for this complication. The type of bisphosphonate may play ...